⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CCCC News
C4 Therapeutics, Inc.
Form 8-K
sec.gov
CCCC
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
globenewswire.com
CCCC
C4 Therapeutics to Participate in Upcoming Conferences
globenewswire.com
CCCC
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CCCC
Form 8-K
sec.gov
CCCC
Form 8-K
sec.gov
CCCC
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com
CCCC
Form 8-K
sec.gov
CCCC
Form 8-K
sec.gov
CCCC
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
globenewswire.com
CCCC